Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 618-630

  Schmitz, Norbert ^a  

^a Department of Hematology and Stem Cell Transplantation ^*  (Germany)

Author keywords

Immune recovery; Mobilized BM for allogeneic transplantation; Peripheral blood hematopoietic cells for allogeneic transplantation; Side effects and long term sequelae of mobilization and collection of HCs; T cell depleted mobilized blood; Transplant related mortality; Transplant related mortality (TRM) after PBHCT

Indexed keywords

EID: 77950338220     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch43     Document Type: Chapter

References (141)

1. Maximow A. Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere. Folia Haemat (Lpz) 1909; 8: 125-41.
2. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702-14.
3. Abrams RA, Glaubiger D, Appelbaum FR et al. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. Blood 1980; 56: 516-20.
4. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-45.
5. Körbling M, Dörken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32.
6. Kessinger A, Armitage JO, Landmark JD et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192-6.
7. Reiffers J, Bernard P, David B et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-15.
8. Socinski MA, Elias A, Schnipper L et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194-8.
9. Dührsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colonystimulating factor on hematopoietic cells in cancer patients. Blood 1988; 72: 2074-81.
10. Kessinger A, Smith DM, Strandjord SE et al. Allogeneic transplantation of blood-derived, Tcell- depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-6.
11. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factormobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-7.
12. Russell NH, Hunter A, Rogers S et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482.
13. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-8.
14. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refracPeripheral Blood Hematopoietic Cells for Allogeneic Transplantation 627 tory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65.
15. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-72.
16. Gratwohl A, Baldomero H, Frauendorfer K et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71-87.
17. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-8.
18. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-5.
19. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
20. Matsunaga T, Sakamaki S, Kohgo Y et al. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993; 11: 103-8.
21. Dreger P, Haferlach T, Eckstein V et al. G-CSFmobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-13.
22. Bishop MR, Tarantolo SR, Jackson JD et al. Allogeneic blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 1601-7.
23. Engelhardt M, Bertz H, Afting M et al. Highversus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 1999; 17: 2160-72.
24. Kröger N, Renges H, Krüger W et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5.
25. Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT). Bone Marrow Transplant 2001; 27: 689-92.
26. de la Rubia J, Martínez, C, Solano C et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplant 1999; 24: 723-8.
27. Ings SJ, Balsa C, Leverett D et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-25.
28. Anderlini P, Körbling M, Dale D et al. Allogeneic stem cell transplantation: considerations for donors. Blood 1997; 90: 903-8.
29. Russell NH, Gratwohl A, Schmitz N. The place of blood stem cells in allogeneic transplantation. Br J Haematol 1996; 93: 747-53.
30. Weaver CH, Birch R, Greco FA et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-47.
31. Anderlini P, Przepiorka D, Seong D et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-12.
32. Brown RA, Adkins D, Goodnough LT et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3067-74.
33. Kroschinsky F, Holig K, Poppe-Thiede K et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90: 1665-71.
34. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colonystimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
35. Sohn SK, Kim JG, Seo KW et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-6.
36. Huhn RD, Yurkow EJ, Tushinski R et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colonystimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 1996; 24: 839-47.
37. Andrews RG, Briddell RA, Knitter GH et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons: enhanced circulation of progenitor cells. Blood 1994; 84: 800-10.
38. Papayannopoulou T, Nakamoto B, Andrews RG et al. In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 1997; 90: 620-9.
39. Fruehauf S, Seeger T, Topaly J. Innovative strategies for PBPC mobilization. Cytotherapy 2005; 7: 438-46.
40. Martelli MF, Aversa F, Bachar-Lustig E et al. Transplants across human leukocyte antigen barriers. Semin Hematol 2002; 39: 48-56.
41. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-81.
42. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstimprimed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-46.
43. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-31.
44. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical sibling with standard-risk leukemia. Blood 2002; 100: 761-71.
45. Uharek L, Gassmann W, Glass B et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79: 1612-21.
46. Singhal S, Powles R, Treleaven J et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-96.
47. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-9.
48. Gorin NC, Labopin M, Rocha V et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043-51.
49. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-70.
50. Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-8.
51. Körbling M, Anderlini P, Durett A et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy- 1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 1996; 18: 1073-9.
52. To LB, Haylock DN, Dowse T et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994; 84: 2930-9.
53. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000; 26: 1-16.
54. Tjonnfjord GE, Steen R, Evensen AS et al. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2795-801.
55. Uchida N, He D, Friera AM et al. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 1997; 89: 1189-96.
56. Steidl U, Kronenwett R, Rohr UP et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 2002; 99: 2037-44.
57. Prosper F, Stroncek D, Verfaillie M. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood 1996; 88: 2033-42.
58. Weaver CH, Longin K, Buckner CD et al. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13: 411-15.
59. Pan L, Delmonte J, Jalonen CK et al. Pretreatment of donor mice with granulocyte colonystimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-9.
60. Kitabayashi A, Hirokawa M, Hatano Y et al. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-a production. Blood 1995; 86: 2220-7.
61. Kusnierz-Glaz CR, Still BJ, Amano M et al. Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood 1997; 89: 2586-95.
62. Mielcarek M, Roecklein BA, Torok-Storb B. CD14+ cells in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood 1996; 87: 574-80.
63. Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colonystimulating factor -mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629-34.
64. Arpinati M, Green CL, Heimfeld S et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-90.
65. Franzke A, Piao W, Lauber J et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003; 102: 734-9.
66. Joshi SS, Lynch JC, Pavletic SZ et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 2001; 98: 1963-70.
67. de Haas M, Kerst JM, van der Schoot E et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885-94.
68. Anderlini P, Przepiorka D, Champlin R et al. Biologic and clinical effects of granulocyte colonystimulating factor in normal individuals. Blood 1996; 88: 2819-25.
69. Schriber JR, Negrin RS. Use and toxicity of the colony-stimulating factors. Drug Saf 1993; 8: 457-68.
70. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997; 96: 415-17.
71. Murata M, Harada M, Kato S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065-71.
72. Stroncek DF, Clay ME, Petzoldt ML et al. Treatment of normal individuals with granulocytecolony- stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601-10.
73. Fossa SD, Poulsen JP, Aaserud A. Alkaline phosphatase and lactate dehydrogenase changes during leucocytosis induced by G-CSF in testicular cancer. Lancet 1992; 340: 1544.
74. Söhngen D, Wienen S, Siebler M et al. Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination. Bone Marrow Transplant 1998; 22: 1087-90.
75. LeBlanc R, Roy J, Demers C et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991-6.
76. Falanga A, Marchetti M, Evangelista V et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colonystimulating factor. Blood 1999; 93: 2506-14.
77. Shimoda K, Okamura S, Inaba S et al. Granulocyte colony-stimulating factor and platelet aggregation. Lancet 1993; 341: 633.
78. Anderlini P, Przepiorka D, Seong D et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155-8.
79. Lindemann A, Herrmann F, Oster W et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989; 74: 2644-51.
80. Wiesneth M, Schreiner T, Friedrich W et al. Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplant 1998; 21: 21-4.
81. Favre G, Beksaç M, Bacigalupo A et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-80.
82. Rowley SC, Donaldson G, Lilleby K et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97: 2541-8.
83. Fortanier C, Kuentz M, Sutton L et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. Bone Marrow Transplant 2002; 29: 145-9.
84. Heldal D, Brinch L, Tjonnfjord G et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant 2002; 29: 479-86.
85. Switzer GE, Goycoolea JM, Dew MA et al. Donating stimulated peripheral blood stem cells vs bone marrow: do donors experience the procedures differently? Bone Marrow Transplant 2001; 27: 917-23.
86. Auquier P, Macquart-Moulin G, Moatti JP et al. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant 1995; 16: 541-7.
87. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-9.
88. Falzetti F, Aversa F, Minelli O et al. Spontaneous rupture of spleen during peripheral blood stemcell mobilisation in a healthy donor. Lancet 1999; 353: 555.
89. Nuamah NM, Goker H, Kilic YA et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006; 91(5 Suppl): ECR08.
90. Balaguer H, Galmes A, Ventayol G et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1.
91. Halter J, Kodera Y, Baldomero H et al. Severe donor events after allogeneic haematopoietic stem cell donation (in preparation).
92. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony stimulating factor. Bone Marrow Transplant 2000; 25: 85-9.
93. Arimura K, Inoue H, Kukita T et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocytecolony stimulating factor alone. Haematologica 2005; 90: ECR10.
94. Parkkali T, Volin L, Sirèn MK et al. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant 1996; 17: 433-4.
95. Hilbe W, Nussbaumer W, Bonatti H et al. Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors (case report). Bone Marrow Transplant 2000; 26: 811-13.
96. Spitzer T, McAfee S, Poliquin C et al. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor (correspondence). Bone Marrow Transplant 1998; 21: 966-7.
97. Adkins DR. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor. J Clin Oncol 1998; 16: 812-13.
98. Bennett CL, Evens AM, Andritsos LA et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-50.
99. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. Br J Haematol 1996; 836: 1-9.
100. Azevedo WM, Aranha FJP, Gouvea JV et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16: 647-53.
101. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-800.
102. Pavletic ZS, Bishop MR, Tarantolo ST et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-16.
103. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-9.
104. Heldal D, Tjonnfjord G, Brinch L et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-36.
105. Mahmoud HK, Fahmy OA, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-8.
106. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-7.
107. Vigorito AC, Azevedo WM, Marques JFC et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematological malignancies. Bone Marrow Transplant 1998; 22: 1145-51.
108. Bishop MR, Tarantolo SR, Geller RB et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-5.
109. Przepiorka D, Smith TL, Folloder J et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigenmatched related donors. Blood 2001; 97: 3405-10.
110. Nash RA, Pepe MS, Storb R et al. Acute graftversus- host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
111. Beelen DW, Ottinger HD, Elmaagacli A et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood 1997; 90: 4725-35.
112. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-9.
113. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-9.
114. Ferrari V, Cacere CR, Machado CM et al. Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anticytomegalovirus immune response and risk for its reactivation. Clin Immunol 2006; 119: 261-71.
115. Lapierre V, Oubouzar N, Aupéring A et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001; 97: 2580-6.
116. Oziel-Taieb S, Faucher-Barbey C, Chabannon C et al. Early and fatal immune haemolysis after so-called "minor" ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997; 19: 1155-6.
117. Salmon JP, Michaux S, Hermanne JP et al. Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion 1999; 39: 824-7.
118. Erker CG, Steins MB, Fischer RJ et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 1382-90.
119. Bensinger W Stem Cell Trialists' Collaborative Group. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38: 539-46.
120. Cao TM, Wong RM, Sheehan K et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33: 279-85.
121. Flowers ME, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-19.
122. Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128-34.
123. Schmitz N, Beksac M, Bacigalupo A et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005; 90: 643-8.
124. Schmitz N, Eapen M, Horowitz MM et al. Longterm outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288-90.
125. Glass B, Uharek L, Zeis M et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graftversus- leukemia effect. Blood 1997; 90: 1694-700.
126. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999; 94: 384-9.
127. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-87.
128. Serody JS, Sparks SD, Lin Y et al. Comparison of granulocyte colony-stimulating factor (GCSF)- mobilized peripheral blood progenitor cells and G-CSF stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434-40.
129. Morton J, Hutchins C, Durrant S. Granulocytecolony stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graftversus- host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186-90.
130. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells or allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-8.
131. Gahrton G, Apperley J, Bacigalupo A et al. An update of allogeneic transplantation with peripheral blood stem cells (PBSCT) as compared to bone marrow (BMT) in multiple myeloma [Abstract]. Bone Marrow Transplant 2002; 29(Suppl 2): S13.
132. Schrezenmeier H, Passweg JR, Marsh JC et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia: a report from the European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. Blood 2007; 110: 1397-400.
133. Eapen M, Horowitz MM, Klein JP et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-80.
134. Bensinger WI, Buckner CD, Shannon-Dorcy K et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-8.
135. Link H, Arseniev L, Bähre O et al. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903-9.
136. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-7.
137. Beelen DW, Peceny R, Elmaagacli A et al. Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study. Bone Marrow Transplant 2000; 26: 823-9.
138. Urbano-Ispizua A, Brunet S, Solano C et al. Allogeneic transplantation of CD34+-selected cells 630 Chapter 43 from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant 2001; 28: 349-54.
139. Cornelissen JJ, van der Holt B, Petersen EJ et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLAidentical allogeneic transplants for hematological malignancies. Exp Hematol 2003; 31: 855-64.
140. Aversa F, Terenzi A, Tabilio A et al. Full haplotype- mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-54.
141. Ringdén O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455-64.